Logo image of SYRE

SPYRE THERAPEUTICS INC (SYRE) Stock Fundamental Analysis

USA - NASDAQ:SYRE - US00773J2024 - Common Stock

16.03 USD
-0.43 (-2.61%)
Last: 10/2/2025, 3:11:01 PM
Fundamental Rating

3

Overall SYRE gets a fundamental rating of 3 out of 10. We evaluated SYRE against 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SYRE as it has an excellent financial health rating, but there are worries on the profitability. SYRE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SYRE had negative earnings in the past year.
SYRE had a negative operating cash flow in the past year.
SYRE had negative earnings in each of the past 5 years.
In the past 5 years SYRE always reported negative operating cash flow.
SYRE Yearly Net Income VS EBIT VS OCF VS FCFSYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a decent Return On Assets value of -34.19%, SYRE is doing good in the industry, outperforming 63.06% of the companies in the same industry.
SYRE's Return On Equity of -40.17% is fine compared to the rest of the industry. SYRE outperforms 72.01% of its industry peers.
Industry RankSector Rank
ROA -34.19%
ROE -40.17%
ROIC N/A
ROA(3y)-83.73%
ROA(5y)-72.22%
ROE(3y)-110.99%
ROE(5y)-93.85%
ROIC(3y)N/A
ROIC(5y)N/A
SYRE Yearly ROA, ROE, ROICSYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SYRE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRE Yearly Profit, Operating, Gross MarginsSYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SYRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SYRE has been increased compared to 1 year ago.
The number of shares outstanding for SYRE has been increased compared to 5 years ago.
There is no outstanding debt for SYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SYRE Yearly Shares OutstandingSYRE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SYRE Yearly Total Debt VS Total AssetsSYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SYRE has an Altman-Z score of 4.30. This indicates that SYRE is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.30, SYRE is doing good in the industry, outperforming 74.63% of the companies in the same industry.
SYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.3
ROIC/WACCN/A
WACC10.03%
SYRE Yearly LT Debt VS Equity VS FCFSYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 11.26 indicates that SYRE has no problem at all paying its short term obligations.
SYRE has a better Current ratio (11.26) than 84.14% of its industry peers.
A Quick Ratio of 11.26 indicates that SYRE has no problem at all paying its short term obligations.
SYRE has a Quick ratio of 11.26. This is amongst the best in the industry. SYRE outperforms 84.14% of its industry peers.
Industry RankSector Rank
Current Ratio 11.26
Quick Ratio 11.26
SYRE Yearly Current Assets VS Current LiabilitesSYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

SYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.09%, which is quite impressive.
SYRE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.47%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SYRE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.26% yearly.
SYRE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -37.52% yearly.
EPS Next Y30.65%
EPS Next 2Y9.75%
EPS Next 3Y6.83%
EPS Next 5Y2.26%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-37.52%

3.3 Evolution

SYRE Yearly Revenue VS EstimatesSYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2028 2029 2030 2031 2032 200M 400M 600M 800M
SYRE Yearly EPS VS EstimatesSYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SYRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRE Price Earnings VS Forward Price EarningsSYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRE Per share dataSYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.75%
EPS Next 3Y6.83%

More info and screens

0

5. Dividend

5.1 Amount

SYRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPYRE THERAPEUTICS INC

NASDAQ:SYRE (10/2/2025, 3:11:01 PM)

16.03

-0.43 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners104.27%
Inst Owner ChangeN/A
Ins Owners8.7%
Ins Owner Change-1.94%
Market Cap968.21M
Analysts88.89
Price Target55.42 (245.73%)
Short Float %25.74%
Short Ratio24.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.81%
Min EPS beat(2)-61.73%
Max EPS beat(2)20.11%
EPS beat(4)2
Avg EPS beat(4)-7.8%
Min EPS beat(4)-61.73%
Max EPS beat(4)20.11%
EPS beat(8)2
Avg EPS beat(8)-279.27%
EPS beat(12)5
Avg EPS beat(12)-182.95%
EPS beat(16)6
Avg EPS beat(16)-139.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.73%
EPS NY rev (3m)2.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)-3.54
EYN/A
EPS(NY)-3.36
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.61
OCFYN/A
SpS0
BVpS8.57
TBVpS8.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.19%
ROE -40.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.73%
ROA(5y)-72.22%
ROE(3y)-110.99%
ROE(5y)-93.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.26
Quick Ratio 11.26
Altman-Z 4.3
F-Score4
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.47%
EPS Next Y30.65%
EPS Next 2Y9.75%
EPS Next 3Y6.83%
EPS Next 5Y2.26%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-37.52%
EBIT growth 1Y16.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.99%
EBIT Next 3Y-5.1%
EBIT Next 5YN/A
FCF growth 1Y-57.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.55%
OCF growth 3YN/A
OCF growth 5YN/A